Ionis reports first quarter 2026 financial results and highlights progress on key programs
Ionis Pharmaceuticals, Inc. (IONS)
Last ionis pharmaceuticals, inc. earnings: 2/26 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ionispharma.com
Company Research
Source: Business Wire
- TRYNGOLZA® (olezarsen) showed increasing demand in FCS driven by strong launch execution –- Olezarsen sNDA accepted by the FDA for Priority Review; sHTG launch preparations on track –– Increasing annual TRYNGOLZA peak net sales guidance to $3B for sHTG –- Zilganersen NDA for Alexander disease accepted for Priority Review, paving way for Ionis’ first independent launch from leading neurology pipeline –- Strong first-quarter performance and outlook for the year supports improved 2026 financial guidance - CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the “Company”) today reported financial results and provided key updates for the first quarter ended March 31, 2026.“Ionis’ strong performance in the first quarter of 2026 underscores the strength of our commercial and R&D engines. Our independent launches are increasingly contributing to revenue, driven by strong commercial execution, and we are on track for two additional groundbreaking independent lau
Show less
Read more
Impact Snapshot
Event Time:
IONS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IONS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IONS alerts
High impacting Ionis Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
IONS
News
- Ionis (IONS) Q1 2026 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Compared to Estimates, Ionis Pharmaceuticals (IONS) Q1 Earnings: A Look at Key Metrics [Yahoo! Finance]Yahoo! Finance
- Ionis reports first quarter 2026 financial results and highlights progress on key programs [Yahoo! Finance]Yahoo! Finance
- Ionis partner GSK announces bepirovirsen accepted for Priority Review and granted Breakthrough Therapy Designation by U.S. FDA as a potential first-in-class medicine for chronic hepatitis BBusiness Wire
- A Look At Ionis Pharmaceuticals (IONS) Valuation After Strong One Year Returns And Recent Pullback [Yahoo! Finance]Yahoo! Finance
IONS
Earnings
- 4/29/26 - Beat
IONS
Sec Filings
- 4/29/26 - Form 10-Q
- 4/29/26 - Form 8-K
- 4/28/26 - Form 144
- IONS's page on the SEC website